Discover

OGN
Organon & Co.
11.26
200 x 12.93
500 x undefined
bid
ask
+
2.66
30.93%
350 @ 08:55 AM
13.24 +1.98 (17.58%)
Ytd 57.04%
1y -7.10%
9.96
day range
11.58
5.69
52 week range
13.24
Open 10.74 Prev Close 8.60 Low 9.96 High 11.58 Mkt Cap 2.93B
Vol 30.14M Avg Vol 5.84M EPS 0.72 P/E 15.64 Forward P/E 2.33
Beta 0.64 Short Ratio 6.50 Inst. Own 77.57% Dividend 0.08 Div Yield 0.88
Ex Div Date 02-23 Earning 05-07 50-d Avg 7.23 200-d Avg 8.36 1yr Est 9.00
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 0.83 N/A N/A N/A
2026-02-12 2025-12 0.73 0.63 -0.1 -13.70%
2025-11-10 2025-09 0.93 1.01 0.08 8.60%
2025-11-10 2025-09 0.93 N/A N/A N/A
2025-08-05 2025-06 0.94 1 0.06 6.38%
2025-08-05 2025-06 0.94 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2026-02-24 Barclays Upgrade Underweight Underweight
2025-12-09 Barclays Upgrade Underweight
2025-11-11 JP Morgan Upgrade Underweight Underweight
2025-11-11 Morgan Stanley Upgrade Equal-Weight Equal-Weight
2025-05-15 Piper Sandler Upgrade Overweight Overweight
2025-05-05 Morgan Stanley Upgrade Equal-Weight Equal-Weight
Profile
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Insider Holder
Date Name Relation Quantity Description
2025-05-04 ALI KEVIN Chief Executive Officer 282.73K Purchase
2025-11-11 COX CARRIE SMITH Officer and Director 0.00 Purchase
2026-03-30 FALCIONE AARON Officer 101.43K Conversion of Exercise of derivative security
2024-09-02 FIEDLER SUSANNE Officer 53.11K Stock Award(Grant)
2026-03-30 KARP DANIEL Officer 69.55K Conversion of Exercise of derivative security
2026-03-30 MORRISSEY JOSEPH T JR Chief Executive Officer 123.12K Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 36.92M 416.42M 14.18%
2025-12-30 Blackrock Inc. 30.97M 349.30M 11.90%
2025-12-30 State Street Corporation 9.60M 108.26M 3.69%
2025-12-30 AQR Capital Management, LLC 8.57M 96.68M 3.29%
2025-12-30 LSV Asset Management 7.47M 84.29M 2.87%
2025-12-30 Massachusetts Financial Services Co. 6.88M 77.63M 2.64%
Fund Ownership
Report Date Organization Position Value Percentage
2026-02-27 iShares Trust-iShares Core S&P Small-Cap ETF 15.79M 178.12M 6.07%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 8.20M 92.46M 3.15%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 5.89M 66.40M 2.26%
2025-12-30 VANGUARD FENWAY FUNDS-Vanguard Equity Income Fund 5.04M 56.84M 1.94%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund 3.80M 42.91M 1.46%
2025-12-30 MFS SERIES TRUST XI-MFS Mid Cap Value Fund 3.70M 41.79M 1.42%
Dividend
Dividend Date
0.02 2026-02-23
0.02 2025-11-20
0.02 2025-08-15
0.02 2025-05-12
0.28 2025-02-24
0.28 2024-11-12